IPO Guru

Q-Line Biotech SME IPO GMP Today and Subject 2 Price

IPO
GMP Price
₹ 0
--
Kostak Rate
₹ 0
Subject to Sauda
₹ 0

Q-Line Biotech SME IPO Grey Market Premium (GMP) today stands at ₹ 0, indicating cautious or neutral market sentiment ahead of listing. The Kostak rate is currently not available, while the Subject to Sauda price is quoted at currently not available. You can check the day-wise GMP trend below to track price movement and investor sentiment over time.

Q-Line Biotech SME IPO is scheduled to open for subscription on May 21, 2026. The public issue aims to raise around ₹251 Cr. and is offered in a price band of ₹326 to ₹343 per share, with a market lot of 400 shares. Investors are closely watching subscription data and grey market trends ahead of the listing.

GMP Trend Chart

Day-wise GMP Trend

Date GMP ↑↓ % Kostak Sub. Sauda
No GMP history available yet.

Q-Line Biotech SME IPO Dates

Event Date
Open Date 21 May, 2026
Close Date 25 May, 2026
Allotment Date 26 May, 2026
Refund Date 27 May, 2026
Credit to Demat 27 May, 2026
Listing Date 29 May, 2026

Q-Line Biotech SME IPO Expected Listing Price

Basis Value
Issue Price (Upper Band) ₹343
Current GMP ₹ 0
GMP-Based Listing Estimate Not yet available
Listing Date 29 May, 2026

Disclaimer: The listing price estimate above is based purely on the current grey market premium (GMP) and is not a guaranteed prediction. GMP is an unofficial, unregulated indicator and can change significantly in the 24–48 hours before listing. Do not make investment decisions based solely on GMP.

Is Q-Line Biotech SME IPO GMP Reliable?

Grey market premium for Q-Line Biotech SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:

  • Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
  • Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
  • Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
  • Cross-check before acting: Review the Q-Line Biotech SME IPO full review for a fundamentals-based assessment before making any grey market trades.

Q-Line Biotech SME IPO IPO Kostak Rate Explained

The Kostak rate for Q-Line Biotech SME IPO is currently not active. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.

The Subject to Sauda price has not been quoted yet. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.

Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.

About Q-Line Biotech SME IPO

Details about Q-Line Biotech will be updated soon.

Frequently Asked Questions about Q-Line Biotech SME IPO

What is the GMP of Q-Line Biotech SME IPO?

The current Grey Market Premium (GMP) of Q-Line Biotech SME IPO is not yet started or active in the market.

What is the Kostak Price of Q-Line Biotech SME IPO?

Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Q-Line Biotech SME IPO is currently not available.

What is the Subject to Sauda Price of Q-Line Biotech SME IPO?

Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.

What is the expected listing price of Q-Line Biotech SME IPO based on GMP?

The listing price estimate is not yet available as GMP has not been established for Q-Line Biotech SME IPO. Check back closer to the subscription date.

Is the GMP of Q-Line Biotech SME IPO increasing or decreasing?

The GMP of Q-Line Biotech SME IPO is currently stable. Track the day-wise GMP table above for the latest movement.

Explore Q-Line Biotech SME IPO Further

For a complete picture before making your investment decision, explore these resources:

Discussion 0

💡
Commenting as
Markdown supported: **bold**, _italics_

No comments yet

Be the first to share your thoughts!

Advertisement